InMed Pharmaceuticals Inc. — Form 10-K
Filed September 9, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 5/100
What the filing says
This 10-K excerpt contains boilerplate exhibits: InMed's insider trading policy (adopted April 22, 2020, standard restrictions on trading MNPI, blackout periods, 10b5-1 plans); auditor consent from CBIZ CPAs P.C. dated September 9, 2026; and SOX 302/906 certifications from CEO Eric A. Adams and CFO Netta Jagpal for fiscal year ended June 30, 2026. No specific transactions, counterparties, dollar amounts, or material changes are disclosed in these exhibits.
Why this rating
Standard compliance exhibits—insider policy, audit consent, and routine executive certifications. No business-material event, transaction, or development disclosed. Pure administrative documentation.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.